Antisense Therapeutics (ASX:ANP) share price tumbles 6% amid capital raise

A man in a white coat holds a laptop in one hand and his head in the other, it's bad news.

Shares in Antisense Therapeutics Limited (ASX: ANP) are tumbling today following a heavily oversubscribed placement.

At the time of writing, the Antisense share price is trading at 22 cents, down 8.33%. This means that its shares have now fallen more than 20% in the past week alone.

What’s driving Antisense shares lower?

A catalyst for today’s fall in Antisense shares is that investors may be concerned about an impending share dilution.

According to its release, Antisense advised that both institutional and sophisticated investors took part in the placement. The firm commitments received will raise $20 million for the company through the issuance of around 83.33 million ordinary shares.

The offer price will be listed at 24 cents apiece and includes one free attaching unlisted option with every 2 shares subscribed. The strike price of the exercisable option will be at a price of 48 cents for each share applied. These options will have an expiry date on the earlier of either 20 December 2024 or 20 business days after the acceleration trigger date.

The board noted that many of the company’s shareholders did not have the opportunity to participate in the offer. As such, an entitlement offer has been put forward which will enable eligible shareholders to apply for 1 new share for every 9.4 existing shares owned.

The issue price is also listed at 24 cents per new share whilst also receiving one free unlisted option for every 2 new shares issued. This is expected to raise an additional $16.8 million for the company.

Funds collected from the placement will be allocated towards covering a number of costs for the ATL1102 Phase IIb/III clinical study. The clinical trial will run for 52-weeks and will be assessed for muscle strength among a number of participants.

About the Antisense share price

It’s been a wild ride for Antisense shareholders, with the company’s shares accelerating by almost 80% year to date. Looking at a longer time frame, the Antisense share price is up around 140% since this time last year.

Based on today’s price, Antisense presides a market capitalisation of around $137.87 million, with approximately 574 million shares outstanding.

The post Antisense Therapeutics (ASX:ANP) share price tumbles 6% amid capital raise appeared first on The Motley Fool Australia.

Should you invest $1,000 in Antisense right now?

Before you consider Antisense, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Antisense wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/3qngeY3

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s